Enopace Biomedical Ltd. has raised $7 million from Italian cardiovascular diseases medical devices company Sorin Group SlA (BIT: SRN). Enopace is developing a neuromodulation system for the treatment of congestive heart failure. The company will use the proceeds to finance initial clinical studies of its technology and further develop its minimally invasive product which stimulates the heart tissue to improve blood flow.
Enopace CEO Amir Dagan said, “The innovative implant is inserted via catheter without the need for invasive coronary surgery. It improves heart function by easing the pressure in the left ventricle.”
Read entire article: http://www.globes.co.il/serveen/globes/docview.asp?did=1000690826&fid=1725